Medical management of Behçet's syndrome

Behçet's Syndrome

Volumn , Issue , 2010, Pages 317-338

  Hamuryudan, Vedat ^a   Kötter, Ina ^b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Azathioprine; Biologic agents; Colchicine; EULAR guidelines; Immunosuppressives; Interferon alpha; Management; Stem cell transplantation; TNF antagonists; Treatment; Uveitis; Vasculitis

Indexed keywords

EID: 79955869739     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-5641-5_19     Document Type: Chapter

References (112)

1. Yurdakul S, Yazici H (2008) Behçet's syndrome. Best Pract Res Clin Rheumatol 22:793-809
2. Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, Yurdakul S, Yazici H (2003) The long-term mortality and morbidity of Behçet's syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 82:60-76 (Pubitemid 36139801)
3. Hamuryudan V, Ozyazgan Y, Hizli N, Mat C, Yurdakul S, Tuzun Y, Senocak M, Yazici H (1997) Azathioprine in Behçet's syndrome: effects on long-term prognosis. Arthritis Rheum 40:769-774 (Pubitemid 127744665)
4. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, Houman MH, Kotter I, Olivieri I, Salvarani C et al (2008) EULAR recommendations for the management of Behçet's disease. Ann Rheum Dis 67:1656-1662
5. Ben-Chetrit E, Levy M (1998) Colchicine: 1998 update. Semin Arthritis Rheum 28:48-59 (Pubitemid 28378084)
6. Matsumura N, Mizushima Y (1975) Leucocyte movement and colchicine treatment in Behçet's disease. Lancet 2:813
7. Mizushima Y, Matsumura N, Mori M, Shimizu T, Fukushima B, Mimura Y, Saito K, Sugiura S (1037) Colchicine in Behçet's disease. Lancet 1977:2
8. Aktulga E, Altac M, Muftuoglu A, Ozyazgan Y, Pazarli H, Tuzun Y, Yalcin B, Yazici H, Yurdakul S (1980) A double blind study of colchicine in Behçet's disease. Haematologica 65:399-402 (Pubitemid 11254772)
9. Yurdakul S, Mat C, Tuzun Y, Ozyazgan Y, Hamuryudan V, Uysal O, Senocak M, Yazici H (2001) A double-blind trial of colchicine in Behçet's syndrome. Arthritis Rheum 44:2686-2692 (Pubitemid 33049346)
10. Rosselet E, Saudan Y, Zenklusen G (1968) Effects of azathioprine ("Imuran") in Behçet's disease. Preliminary therapeutic results. Ophthalmologica 156:218-226
11. Yazici H, Pazarli H, Barnes CG, Tuzun Y, Ozyazgan Y, Silman A, Serdaroglu S, Oguz V, Yurdakul S, Lovatt GE et al (1990) A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med 322:281-285 (Pubitemid 20046329)
12. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, Houman MH, Kotter I, Olivieri I, Salvarani C et al (2009) Management of Behçet's disease: a systematic literature review for the EULAR evidence based recommendations for the management of Behçet's disease. Ann Rheum Dis 68:1528-1534
13. Hamuryudan V, Ozyazgan Y, Fresko Y, Mat C, Yurdakul S, Yazici H (2002) Interferon alfa combined with azathioprine for the uveitis of Behçet's disease: an open study. Isr Med Assoc J 4:928-930 (Pubitemid 35291273)
14. Hamuryudan V, Er T, Seyahi E, Akman C, Tuzun H, Fresko I, Yurdakul S, Numan F, Yazici H (2004) Pulmonary artery aneurysms in Behçet's syndrome. Am J Med 117:867-870 (Pubitemid 39602798)
15. Kaklamani VG, Kaklamanis PG (2001) Treatment of Behçet's disease-an update. Semin Arthritis Rheum 30:299-312
16. BenEzra D, Cohen E, Chajek T, Friedman G, Pizanti S, de Courten C, Harris W (1988) Evaluation of conventional therapy versus cyclosporine A in Behçet's syndrome. Transplant Proc 20:136-143
17. Saenz A, Ausejo M, Shea B, Wells G, Welch V, Tugwell P (2000) Pharmacotherapy for Behçet's syndrome. Cochrane Database Syst Rev (2) CD001084
18. Ozyazgan Y, Yurdakul S, Yazici H, Tuzun B, Iscimen A, Tuzun Y, Aktunc T, Pazarli H, Hamuryudan V, Muftuoglu A (1992) Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial. Br J Ophthalmol 76:241-243
19. Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G (1989) Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease. Lancet 1:1093-1096 (Pubitemid 19128039)
20. Cantini F, Salvarani C, Niccoli L, Padula A, Arena AI, Bellandi F, Macchioni P, Olivieri I (1999) Treatment of thrombophlebitis of Behçet's disease with low dose cyclosporin A. Clin Exp Rheumatol 17:391-392 (Pubitemid 29265696)
21. Muftuoglu AU, Pazarli H, Yurdakul S, Yazici H, Ulku BY, Tuzun Y, Serdaroglu S, Altug E, Bahcecioglu H, Gungen G (1987) Short term cyclosporin A treatment of Behçet's disease. Br J Ophthalmol 71:387-390 (Pubitemid 17072286)
22. Akpolat T, Diri B, Oguz Y, Yilmaz E, Yavuz M, Dilek M (2003) Behçet's disease and renal failure. Nephrol Dial Transplant 18:888-891
23. Kotake S, Higashi K, Yoshikawa K, Sasamoto Y, Okamoto T, Matsuda H (1999) Central nervous system symptoms in patients with Behçet's disease receiving cyclosporine therapy. Ophthalmology 106:586-589 (Pubitemid 30191596)
24. Kato Y, Numaga J, Kato S, Kaburaki T, Kawashima H, Fujino Y (2001) Central nervous system symptoms in a population of Behçet's disease patients with refractory uveitis treated with cyclosporine A. Clin Exp Ophthalmol 29:335-336 (Pubitemid 33039850)
25. Kotter I, Gunaydin I, Batra M, Vonthein R, Stubiger N, Fierlbeck G, Melms A (2006) CNS involvement occurs more frequently in patients with Behçet's disease under cyclosporin A (CSA) than under other medications-results of a retrospective analysis of 117 cases. Clin Rheumatol 25:482-486 (Pubitemid 44137619)
26. Akman-Demir G, Ayranci O, Kurtuncu M, Vanli EN, Mutlu M, Tugal-Tutkun I (2008) Cyclosporine for Behçet's uveitis: is it associated with an increased risk of neurological involvement? Clin Exp Rheumatol 26:S84-S90
27. Perri AJ 3rd, Hsu S (2003) A review of thalidomide's history and current dermatological applications. Dermatol Online J 9:5
28. Direskeneli H, Ergun T, Yavuz S, Hamuryudan V, Eksioglu-Demiralp E (2008) Thalidomide has both anti-inflammatory and regulatory effects in Behçet's disease. Clin Rheumatol 27:373-375
29. Saylan T, Saltik I (1982) Thalidomide in the treatment of Behçet's syndrome. Arch Dermatol 118:536
30. Jorizzo JL, Schmalstieg FC, Solomon AR Jr, Cavallo T, Taylor RS 3rd, Rudloff HB, Schmalstieg EJ, Daniels JC (1986) Thalidomide effects in Behçet's syndrome and pustular vasculitis. Arch Intern Med 146:878-881 (Pubitemid 16116664)
31. Denman AM, Graham E, Howe L, Denman EJ, Lightman S (1993) Low dose thalidomide treatment of Behçet's syndrome. In: Wechsler B, Godeau P (eds) Behçet's disease. Proceedings of the 6th international conference on Behçet's disease. Excerpta Medica, Amsterdam, pp 649-653
32. Hamza MH (1986) Treatment of Behçet's disease with thalidomide. Clin Rheumatol 5:365-371
33. Brik R, Shamali H, Bergman R (2001) Successful thalidomide treatment of severe infantile Behçet's disease. Pediatr Dermatol 18:143-145 (Pubitemid 32410960)
34. Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, Zwingenberger K, Yazici H (1998) Thalidomide in the treatment of the mucocutaneous lesions of the Behçet's syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 128:443-450
35. Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, Gopal AV, Morris C, Toor A, Siegel E, Fink L et al (2001) Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98:1614-1615
36. Kobayashi K, Ueno F, Bito S, Iwao Y, Fukushima T, Hiwatashi N, Igarashi M, Iizuka BE, Matsuda T, Matsui T et al (2007) Development of consensus statements for the diagnosis and management of intestinal Behçet's disease using a modified Delphi approach. J Gastroenterol 42:737-745 (Pubitemid 47456761)
37. Mat C, Yurdakul S, Uysal S, Gogus F, Ozyazgan Y, Uysal O, Fresko I, Yazici H (2006) A double-blind trial of depot corticosteroids in Behçet's syndrome. Rheumatology (Oxford) 45:348-352 (Pubitemid 43372853)
38. O'Duffy JD, Robertson DM, Goldstein NP (1984) Chlorambucil in the treatment of uveitis and meningoencephalitis of Behçet's disease. Am J Med 76:75-84 (Pubitemid 14216363)
39. Mudun BA, Ergen A, Ipcioglu SU, Burumcek EY, Durlu Y, Arslan MO (2001) Short-term chlorambucil for refractory uveitis in Behçet's disease. Ocul Immunol Inflamm 9:219-229 (Pubitemid 34286623)
40. Palmer RG, Dore CJ, Denman AM (1984) Chlorambucil-induced chromosome damage to human lymphocytes is dose-dependent and cumulative. Lancet 1:246-249 (Pubitemid 14181864)
41. Tabbara KF (1983) Chlorambucil in Behçet's disease. A reappraisal. Ophthalmology 90:906-908
42. Sakane T, Mochizuki M, Inaba G, Masuda K (1995) A phase II study of FK506 (tacrolimus) on refractory uveitis associated with Behçet's disease and allied conditions. Ryumachi 35:802-813
43. Davatchi F, Shahram F, Chams H, Jamshidi AR, Nadji A, Chams C, Akbarian M, Gharibdoost F (2003) High dose methotrexate for ocular lesions of Behçet's disease. Preliminary short-term results. Adv Exp Med Biol 528:579-584
44. Adler YD, Mansmann U, Zouboulis CC (2001) Mycophenolate mofetil is ineffective in the treatment of mucocutaneous Adamantiades-Behçet's disease. Dermatology 203:322-324 (Pubitemid 34045195)
45. Mumcu G, Inanc N, Yavuz S, Direskeneli H (2007) The role of infectious agents in the pathogenesis, clinical manifestations and treatment strategies in Behçet's disease. Clin Exp Rheumatol 25:S27-S33
46. Calguneri M, Kiraz S, Ertenli I, Benekli M, Karaarslan Y, Celik I (1996) The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behçet's disease. A randomized clinical trial. Arthritis Rheum 39:2062-2065
47. Calguneri M, Ertenli I, Kiraz S, Erman M, Celik I (1996) Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behçet's disease. Dermatology 192:125-128
48. Mumcu G, Ergun T, Elbir Y, Eksioglu-Demiralp E, Yavuz S, Atalay T, Direskeneli H (2005) Clinical and immunological effects of azithromycin in Behçet's disease. J Oral Pathol Med 34:13-16 (Pubitemid 40142924)
49. Kaneko F, Oyama N, Nishibu A (1997) Streptococcal infection in the pathogenesis of Behçet's disease and clinical effects of minocycline on the disease symptoms. Yonsei Med J 38:444-454
50. Kahraman O, Celebi-Onder S, Kamali S (2003) Long term course of deep vein thrombosis in patients with Behçet's disease. In: Proceedings of the American College of Rheumatology 67th annual meeting, Orlando, FL, Wiley, NJ, p S385
51. Ahn JK, Lee YS, Jeon CH, Koh EM, Cha HS (2008) Treatment of venous thrombosis associated with Behçet's disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. Clin Rheumatol 27:201-205
52. Sharquie KE, Najim RA, Abu-Raghif AR (2002) Dapsone in Behçet's disease: a doubleblind, placebo-controlled, cross-over study. J Dermatol 29:267-279 (Pubitemid 34742240)
53. Matsuda T, Ohno S, Hirohata S, Miyanaga Y, Ujihara H, Inaba G, Nakamura S, Tanaka S, Kogure M, Mizushima Y (2003) Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behçet's disease: a randomised, double-blind, placebo-controlled study. Drugs R D 4:19-28 (Pubitemid 37062641)
54. Alpsoy E, Er H, Durusoy C, Yilmaz E (1999) The use of sucralfate suspension in the treatment of oral and genital ulceration of Behçet's disease: a randomized, placebo-controlled, double-blind study. Arch Dermatol 135:529-532 (Pubitemid 29222295)
55. de Merieux P, Spitler LE, Paulus HE (1981) Treatment of Behçet's syndrome with levamisole. Arthritis Rheum 24:64-70
56. Wolf RE, Fudenberg HH, Welch TM, Spitler LE, Ziff M (1977) Treatment of Bechcet's syndrome with transfer factor. JAMA 238:869-871 (Pubitemid 8179268)
57. Davies UM, Palmer RG, Denman AM (1988) Treatment with acyclovir does not affect orogenital ulcers in Behçet's syndrome: a randomized double-blind trial. Br J Rheumatol 27:300-302
58. Tasli L, Mat C, De Simone C, Yazici H (2006) Lactobacilli lozenges in the management of oral ulcers of Behçet's syndrome. Clin Exp Rheumatol 24:S83-S86 (Pubitemid 44696884)
59. Ergun T, Gurbuz O, Yurdakul S, Hamuryudan V, Bekiroglu N, Yazici H (1997) Topical cyclosporine-A for treatment of oral ulcers of Behçet's syndrome. Int J Dermatol 36:720 (Pubitemid 27452162)
60. Kose O, Dinc A, Simsek I (2009) Randomized trial of pimecrolimus cream plus colchicine tablets versus colchicine tablets in the treatment of genital ulcers in Behçet's disease. Dermatology 218:140-145
61. Hamuryudan V, Yurdakul S, Rosenkaimer F, Yazici H (1991) Inefficacy of topical alpha interferon alpha interferon in the treatment of oral ulcers of Behçet's syndrome: a randomized, double blind trial. Br J Rheumatol 30:395-396
62. Bacanli A, Yerebakan Dicle O, Parmaksizoglu B, Yilmaz E, Alpsoy E (2006) Topical granulocyte colony-stimulating factor for the treatment of oral and genital ulcers of patients with Behçet's disease. J Eur Acad Dermatol Venereol 20:931-935
63. Yasui K, Ohta K, Kobayashi M, Aizawa T, Komiyama A (1996) Successful treatment of Behçet's disease with pentoxifylline. Ann Intern Med 124:891-893
64. Simsek H, Dundar S, Telatar H (1991) Treatment of Behçet's disease with indomethacin. Int J Dermatol 30:54-57
65. Takeuchi A, Mori M, Hashimoto A, Chihara T (1984) Efficacy of oxaprozin in the treatment of articular symptoms of Behçet's disease. Clin Rheumatol 3:397-399 (Pubitemid 15072125)
66. Moral F, Hamuryudan V, Yurdakul S, Yazici H (1995) Inefficacy of azapropazone in the acute arthritis of Behçet's syndrome: a randomized, double blind, placebo controlled study. Clin Exp Rheumatol 13:493-495
67. Tsambaos D, Eichelberg D, Goos M (1986) Behçet's syndrome: treatment with recombinant leukocyte alpha-interferon. Arch Dermatol Res 278:335-336 (Pubitemid 16096033)
68. Hamuryudan V, Moral F, Yurdakul S, Mat C, Tuzun Y, Ozyazgan Y, Direskeneli H, Akoglu T, Yazici H (1994) Systemic interferon alpha 2b treatment in Behçet's syndrome. J Rheumatol 21:1098-1100 (Pubitemid 24182284)
69. Demiroglu H, Ozcebe OI, Barista I, Dundar S, Eldem B (2000) Interferon alfa-2b, colchicine, and benzathine penicillin versus colchicine and benzathine penicillin in Behçet's disease: a randomised trial. Lancet 355:605-609 (Pubitemid 30099466)
70. Horton R (2000) Retraction: interferon alfa-2b⋯in Behçet's disease. Lancet 356:1292
71. Alpsoy E, Durusoy C, Yilmaz E, Ozgurel Y, Ermis O, Yazar S, Basaran E (2002) Interferon alfa-2a in the treatment of Behçet's disease: a randomized placebo-controlled and doubleblind study. Arch Dermatol 138:467-471 (Pubitemid 34290024)
72. Kotter I, Zierhut M, Eckstein AK, Vonthein R, Ness T, Gunaydin I, Grimbacher B, Blaschke S, Meyer-Riemann W, Peter HH et al (2003) Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 87:423-431 (Pubitemid 36399030)
73. Kotter I, Gunaydin I, Zierhut M, Stubiger N (2004) The use of interferon alpha in Behçet's disease: review of the literature. Semin Arthritis Rheum 33:320-335 (Pubitemid 38496041)
74. Kotter I, Vonthein R, Zierhut M, Eckstein AK, Ness T, Gunaydin I, Grimbacher B, Blaschke S, Peter HH, Stubiger N (2004) Differential efficacy of human recombinant interferonalpha2a on ocular and extraocular manifestations of Behçet's disease: results of an open 4-center trial. Semin Arthritis Rheum 33:311-319 (Pubitemid 38496040)
75. Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M (2006) Results of interferon-alfa therapy in patients with Behçet's uveitis. Graefes Arch Clin Exp Ophthalmol 244:1692-1695 (Pubitemid 44830831)
76. Gueudry J, Wechsler B, Terrada C, Gendron G, Cassoux N, Fardeau C, Lehoang P, Piette JC, Bodaghi B (2008) Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet's disease. Am J Ophthalmol 146:837-844, e831
77. Krause L, Altenburg A, Pleyer U, Kohler AK, Zouboulis CC, Foerster MH (2008) Longterm visual prognosis of patients with ocular Adamantiades- Behçet's disease treated with interferonalpha-2a. J Rheumatol 35:896-903 (Pubitemid 351747134)
78. Deuter CM, Kotter I, Gunaydin I, Zierhut M, Stubiger N (2004) Ocular involvement in Behçet's disease: first 5-year-results for visual development after treatment with interferon alfa-2a. Ophthalmologe 101:129-134 (Pubitemid 38295555)
79. Krause L, Kohler AK, Altenburg A, Papoutsis N, Zouboulis CC, Pleyer U, Stroux A, Foerster MH (2009) Ocular involvement in Adamantiades-Behçet's disease in Berlin, Germany. Graefes Arch Clin Exp Ophthalmol 247:661-666
80. Deuter C, Kotter I, Mohle A, Vonthein R, Stubiger N, Zierhut M (2009) Long-term observations of vision and relapse-free intervals in patients with severe uveitis due to Behçet's disease treated with interferon alfa. ARVO Abstract 2009 No. 2694
81. Deuter CM, Kotter I, Wallace GR, Murray PI, Stubiger N, Zierhut M (2008) Behçet's disease: ocular effects and treatment. Prog Retin Eye Res 27:111-136
82. Guillaume-Czitrom S, Berger C, Pajot C, Bodaghi B, Wechsler B, Kone-Paut I (2007) Efficacy and safety of interferon-alpha in the treatment of corticodependent uveitis of paediatric Behçet's disease. Rheumatology (Oxford) 46:1570-1573 (Pubitemid 47500572)
83. Kuemmerle-Deschner JB, Tzaribachev N, Deuter C, Zierhut M, Batra M, Koetter I (2008) Interferon-alpha-a new therapeutic option in refractory juvenile Behçet's disease with CNS involvement. Rheumatology (Oxford) 47:1051-1053 (Pubitemid 351865931)
84. Hauschild A, Kahler KC, Schafer M, Fluck M (2008) Interdisciplinary management recommendations for toxicity associated with interferon-alfa therapy. J Dtsch Dermatol Ges 6:829-837, 829-838
85. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN (2001) Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet 358:295-296 (Pubitemid 32738970)
86. Benitez-del-Castillo JM, Martinez-de-la-Casa JM, Pato-Cour E, Mendez-Fernandez R, Lopez-Abad C, Matilla M, Garcia-Sanchez J (2005) (2005) Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab). Eye 19:841-845 (Pubitemid 41195135)
87. Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S, Hamuryudan V, Yazici H (2005) Short term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. J Rheumatol 32:98-105 (Pubitemid 40092599)
88. Tabbara KF, Al-Hemidan AI (2008) Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet's disease. Am J Ophthalmol 146:845-850, e841
89. Ribi C, Sztajzel R, Delavelle J, Chizzolini C (2005) Efficacy of TNF alpha blockade in cyclophosphamide resistant neuro-Behçet's disease. J Neurol Neurosurg Psychiatry 76:1733-1735 (Pubitemid 41697647)
90. Sarwar H, McGrath H Jr, Espinoza LR (2005) Successful treatment of long-standing neuro-Behçet's disease with infliximab. J Rheumatol 32:181-183 (Pubitemid 40092611)
91. Alty JE, Monaghan TM, Bamford JM (2007) A patient with neuro-Behçet's disease is successfully treated with etanercept: further evidence for the value of TNFalpha blockade. Clin Neurol Neurosurg 109:279-281
92. Belzunegui J, Lopez L, Paniagua I, Intxausti JJ, Maiz O (2008) Efficacy of infliximab and adalimumab in the treatment of a patient with severe neuro-Behçet's disease. Clin Exp Rheumatol 26:S133-S134
93. Kikuchi H, Aramaki K, Hirohata S (2008) Effect of infliximab in progressive neuro-Behçet's syndrome. J Neurol Sci 272:99-105
94. Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG, Papaefthimiou S, Markomichelakis N (2004) Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet's disease. Ann Intern Med 140:404-406 (Pubitemid 38268925)
95. Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, Sugita S, Ueno S, Yoshizaki K, Inaba G (2004) Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol 31:1362-1368 (Pubitemid 38879203)
96. Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, Gul A (2005) Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial. Arthritis Rheum 52:2478-2484 (Pubitemid 41117435)
97. Tognon S, Graziani G, Marcolongo R (2007) Anti-TNF-alpha therapy in seven patients with Behçet's uveitis: advantages and controversial aspects. Ann N Y Acad Sci 1110:474-484 (Pubitemid 350043037)
98. Sfikakis PP, Markomichelakis N, Alpsoy E, Assaad-Khalil S, Bodaghi B, Gul A, Ohno S, Pipitone N, Schirmer M, Stanford M et al (2007) Anti-TNF therapy in the management of Behçet's disease-review and basis for recommendations. Rheumatology (Oxford) 46:736-741 (Pubitemid 47061701)
99. Song IH, Appel H, Haibel H, Loddenkemper C, Braun J, Sieper J, Rudwaleit M (2008) New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept. J Rheumatol 35:532-536 (Pubitemid 351374434)
100. Lim LL, Fraunfelder FW, Rosenbaum JT (2007) Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 56:3248-3252 (Pubitemid 47585419)
101. Foeldvari I, Nielsen S, Kummerle-Deschner J, Espada G, Horneff G, Bica B, Olivieri AN, Wierk A, Saurenmann RK (2007) Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol 34:1146-1150 (Pubitemid 46774863)
102. Lockwood CM, Hale G, Waldman H, Jayne DR (2003) Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. Rheumatology (Oxford) 42:1539-1544 (Pubitemid 37508929)
103. Buggage RR, Levy-Clarke G, Sen HN, Ursea R, Srivastava SK, Suhler EB, Altemare C, Velez G, Ragheb J, Chan CC et al (2007) A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease. Ocul Immunol Inflamm 15:63-70 (Pubitemid 46897689)
104. Sadreddini S, Noshad H, Molaeefard M, Noshad R (2008) Treatment of retinal vasculitis in Behçet's disease with rituximab. Mod Rheumatol 18:306-308
105. Botsios C, Sfriso P, Furlan A, Punzi L, Dinarello CA (2008) Resistant Behçet's disease responsive to anakinra. Ann Intern Med 149:284-286
106. De Cata A, Intiso D, Bernal M, Molinaro F, Mazzoccoli G, D'Alessandro V, Greco A, Curci S, Sperandeo M, Frusciante V et al (2007) Prolonged remission of neuro-Behçet's disease following autologous transplantation. Int J Immunopathol Pharmacol 20:91-96 (Pubitemid 46506879)
107. Rossi G, Moretta A, Locatelli F (2004) Autologous hematopoietic stem cell transplantation for severe/refractory intestinal Behçet's disease. Blood 103:748-750 (Pubitemid 38140118)
108. Maurer B, Hensel M, Max R, Fiehn C, Ho AD, Lorenz HM (2006) Autologous haematopoietic stem cell transplantation for Behçet's disease with pulmonary involvement: analysis after 5 years of follow up. Ann Rheum Dis 65:127-129 (Pubitemid 41815655)
109. Tomonari A, Tojo A, Takahashi T, Iseki T, Ooi J, Takahashi S, Nagamura F, Uchimaru K, Asano S (2004) Resolution of Behçet's disease after HLA-mismatched unrelated cord blood transplantation for myelodysplastic syndrome. Ann Hematol 83:464-466 (Pubitemid 38877972)
110. Marmont AM, Gualandi F, Piaggio G, Podesta M (2006) Teresa van Lint M, Bacigalupo A, Nobili F: allogeneic bone marrow transplantation (BMT) for refractory Behçet's disease with severe CNS involvement. Bone Marrow Transplant 37:1061-1063
111. Nonami A, Takenaka K, Sumida C, Aizawa K, Kamezaki K, Miyamoto T, Harada N, Nagafuji K, Teshima T, Harada M (2007) Successful treatment of myelodysplastic syndrome (MDS)-related intestinal Behçet's disease by up-front cord blood transplantation. Intern Med 46:1753-1756 (Pubitemid 350111151)
112. Daikeler T, Kotter I, Bocelli Tyndall C, Apperley J, Attarbaschi A, Guardiola P, Gratwohl A, Jantunen E, Marmont A, Porretto F et al (2007) Haematopoietic stem cell transplantation for vasculitis including Behçet's disease and polychondritis: a retrospective analysis of patients recorded in the European bone marrow transplantation and European league against rheumatism databases and a review of the literature. Ann Rheum Dis 66:202-207 (Pubitemid 46226055)